--- title: "Scribe Therapeutics (NASDAQ:SCTX) Sets New 52-Week High After Analyst Upgrade" type: "News" locale: "en" url: "https://longbridge.com/en/news/296375400.md" description: "Scribe Therapeutics (NASDAQ:SCTX) reached a new 52-week high of $28.81 following an analyst upgrade by Guggenheim to a strong-buy rating. Other firms, including Leerink Partners and Wells Fargo, also issued positive ratings with target prices of $37 and $60 respectively. The stock's consensus rating is 'Buy' with an average target of $49. Additionally, insiders Behzad Aghazadeh and Bio Fund Ii L.P. Ah recently purchased significant shares." datetime: "2026-08-19T15:20:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296375400.md) - [en](https://longbridge.com/en/news/296375400.md) - [zh-HK](https://longbridge.com/zh-HK/news/296375400.md) generator: "portal-rs" --- # Scribe Therapeutics (NASDAQ:SCTX) Sets New 52-Week High After Analyst Upgrade Scribe Therapeutics Inc. (NASDAQ:SCTX - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after Guggenheim upgraded the stock to a strong-buy rating. The stock traded as high as $28.81 and last traded at $28.63, with a volume of 77834 shares trading hands. The stock had previously closed at $27.11. Get **Scribe Therapeutics** alerts: A number of other research analysts have also recently weighed in on SCTX. Leerink Partners started coverage on Scribe Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $37.00 target price on the stock. Wells Fargo & Company assumed coverage on Scribe Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $60.00 price target for the company. Finally, Wall Street Zen upgraded Scribe Therapeutics to a "hold" rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to MarketBeat.com, Scribe Therapeutics currently has a consensus rating of "Buy" and an average target price of $49.00. **View Our Latest Report on SCTX** ## Insider Buying and Selling In related news, Director Behzad Aghazadeh purchased 7,905 shares of Scribe Therapeutics stock in a transaction that occurred on Tuesday, July 28th. The shares were purchased at an average cost of $18.25 per share, with a total value of $144,266.25. Following the transaction, the director owned 3,088,888 shares of the company's stock, valued at approximately $56,372,206. The trade was a 0.26% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of Scribe Therapeutics stock in a transaction that occurred on Monday, July 27th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. Following the completion of the transaction, the insider directly owned 2,385,075 shares in the company, valued at $35,776,125. This represents a 16.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 3,727,237 shares of company stock worth $56,291,746 in the last ninety days. ## Scribe Therapeutics Trading Up 5.0% ## Scribe Therapeutics Company Profile (Get Free Report) Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif. ## Further Reading - Five stocks we like better than Scribe Therapeutics - Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same? - AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3? - The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell - Tesla's Cybercab Launch Could Reshape Margins for Uber and Lyft *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Scribe Therapeutics Right Now? Before you consider Scribe Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scribe Therapeutics wasn't on the list. While Scribe Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md) ## Related News & Research - [SCTX: CRISPR-driven therapies show promise for durable cardiovascular disease prevention and treatment](https://longbridge.com/en/news/297828691.md) - [BlossomHill Therapeutics, Inc.'s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)](https://longbridge.com/en/news/298403236.md) - [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th](https://longbridge.com/en/news/298168859.md) - [Morgan Stanley Remains a Buy on AgomAb Therapeutics NV ADR (AGMB)](https://longbridge.com/en/news/298315044.md) - [Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/298407524.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**